FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022201364> ?p ?o ?g. }

• W2022201364 endingPage "2446" @default.
• W2022201364 startingPage "2438" @default.
• W2022201364 abstract "BACKGROUND: Everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, affects tumor growth by blocking growth factor stimulation, arresting cell cycle progression, and inhibiting angiogenesis. mTOR inhibitors and agents with primarily antiangiogenic activity have been shown to have efficacy in renal cell cancer (RCC). This phase 2 study assessed the efficacy of daily oral dosing with everolimus in patients with RCC. METHODS: Patients had confirmed predominantly clear cell RCC; had received ≤1 prior therapy; and had progressive, measurable metastatic disease. Everolimus was given at a dose of 10 mg daily orally without interruption (28-day cycle), with dose modifications for toxicity (graded according to National Cancer Institute Common Toxicity Criteria, version 3.0). Patients were evaluated every 2 cycles (8 weeks) using Response Evaluation Criteria in Solid Tumors (RECIST). RESULTS: Of 41 enrolled patients, 39 were treated and evaluable for safety, 37 of whom were evaluable for response (2 patients withdrew after the first week of therapy). Approximately 78% of the patients were male, the median age was 60 years, 93% had a Zubrod performance status of 0 to 1, and 83% had received prior therapy. The median progression-free survival (PFS) was 11.2 months and the median overall survival was 22.1 months. Partial responses were observed in 5 (14%) patients, stable disease lasting ≥3 months was reported in 27 (73%) patients, and stable disease lasting ≥6 months was reported in 21 (57%) patients. Nausea (38% of patients), anorexia (38% of patients), diarrhea (31% of patients), stomatitis (31% of patients), pneumonitis (31% of patients), and rash (26% of patients) were common. Grade 3 of 4 adverse events included pneumonitis (18% of patients); transaminase elevations (10% of patients); thrombocytopenia, hyperglycemia, and alkaline phosphatase elevations (8% each of patients); and hyperlipidemia (5% of patients). CONCLUSIONS: In the current study, everolimus demonstrated encouraging antitumor activity against metastatic RCC as indicated by a PFS ≥ 6 months for approximately 70% of patients. Cancer 2009. © 2009 American Cancer Society." @default.
• W2022201364 created "2016-06-24" @default.
• W2022201364 creator A5000343593 @default.
• W2022201364 creator A5014373184 @default.
• W2022201364 creator A5042781589 @default.
• W2022201364 creator A5067127751 @default.
• W2022201364 creator A5083677355 @default.
• W2022201364 date "2009-06-01" @default.
• W2022201364 modified "2023-10-06" @default.
• W2022201364 title "A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer" @default.
• W2022201364 cites W1974952755 @default.
• W2022201364 cites W1986026265 @default.
• W2022201364 cites W1999966467 @default.
• W2022201364 cites W2008904919 @default.
• W2022201364 cites W2010538519 @default.
• W2022201364 cites W2012945996 @default.
• W2022201364 cites W2015644147 @default.
• W2022201364 cites W2060826753 @default.
• W2022201364 cites W2068555261 @default.
• W2022201364 cites W2098176107 @default.
• W2022201364 cites W2106453307 @default.
• W2022201364 cites W2118677643 @default.
• W2022201364 cites W2131818083 @default.
• W2022201364 cites W2136530530 @default.
• W2022201364 cites W2139248078 @default.
• W2022201364 cites W2147394591 @default.
• W2022201364 cites W2149218373 @default.
• W2022201364 cites W2149456801 @default.
• W2022201364 cites W2153493705 @default.
• W2022201364 cites W2153867442 @default.
• W2022201364 cites W2160363302 @default.
• W2022201364 cites W2164977235 @default.
• W2022201364 cites W2165848665 @default.
• W2022201364 cites W2231449007 @default.
• W2022201364 cites W2273695166 @default.
• W2022201364 cites W2274092844 @default.
• W2022201364 cites W2280859858 @default.
• W2022201364 cites W2309807249 @default.
• W2022201364 cites W2322553446 @default.
• W2022201364 cites W3009736595 @default.
• W2022201364 cites W4245134796 @default.
• W2022201364 doi "https://doi.org/10.1002/cncr.24280" @default.
• W2022201364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19306412" @default.
• W2022201364 hasPublicationYear "2009" @default.
• W2022201364 type Work @default.
• W2022201364 sameAs 2022201364 @default.
• W2022201364 citedByCount "188" @default.
• W2022201364 countsByYear W20222013642012 @default.
• W2022201364 countsByYear W20222013642013 @default.
• W2022201364 countsByYear W20222013642014 @default.
• W2022201364 countsByYear W20222013642015 @default.
• W2022201364 countsByYear W20222013642016 @default.
• W2022201364 countsByYear W20222013642017 @default.
• W2022201364 countsByYear W20222013642018 @default.
• W2022201364 countsByYear W20222013642019 @default.
• W2022201364 countsByYear W20222013642020 @default.
• W2022201364 countsByYear W20222013642021 @default.
• W2022201364 countsByYear W20222013642022 @default.
• W2022201364 countsByYear W20222013642023 @default.
• W2022201364 crossrefType "journal-article" @default.
• W2022201364 hasAuthorship W2022201364A5000343593 @default.
• W2022201364 hasAuthorship W2022201364A5014373184 @default.
• W2022201364 hasAuthorship W2022201364A5042781589 @default.
• W2022201364 hasAuthorship W2022201364A5067127751 @default.
• W2022201364 hasAuthorship W2022201364A5083677355 @default.
• W2022201364 hasBestOaLocation W20222013641 @default.
• W2022201364 hasConcept C121608353 @default.
• W2022201364 hasConcept C126322002 @default.
• W2022201364 hasConcept C141071460 @default.
• W2022201364 hasConcept C143998085 @default.
• W2022201364 hasConcept C183713625 @default.
• W2022201364 hasConcept C185592680 @default.
• W2022201364 hasConcept C190283241 @default.
• W2022201364 hasConcept C2776694085 @default.
• W2022201364 hasConcept C2776820818 @default.
• W2022201364 hasConcept C2777472916 @default.
• W2022201364 hasConcept C2778496288 @default.
• W2022201364 hasConcept C2778822529 @default.
• W2022201364 hasConcept C2779051857 @default.
• W2022201364 hasConcept C2779490328 @default.
• W2022201364 hasConcept C2779699572 @default.
• W2022201364 hasConcept C2779984678 @default.
• W2022201364 hasConcept C2780580376 @default.
• W2022201364 hasConcept C2781413609 @default.
• W2022201364 hasConcept C29730261 @default.
• W2022201364 hasConcept C31760486 @default.
• W2022201364 hasConcept C55493867 @default.
• W2022201364 hasConcept C71924100 @default.
• W2022201364 hasConcept C86554907 @default.
• W2022201364 hasConcept C90924648 @default.
• W2022201364 hasConceptScore W2022201364C121608353 @default.
• W2022201364 hasConceptScore W2022201364C126322002 @default.
• W2022201364 hasConceptScore W2022201364C141071460 @default.
• W2022201364 hasConceptScore W2022201364C143998085 @default.
• W2022201364 hasConceptScore W2022201364C183713625 @default.
• W2022201364 hasConceptScore W2022201364C185592680 @default.
• W2022201364 hasConceptScore W2022201364C190283241 @default.
• W2022201364 hasConceptScore W2022201364C2776694085 @default.

• next